Systematic toxicity mechanism analysis of proton pump inhibitors: An in silico study

Chemical Research in Toxicology

Volumn 28, Issue 3, 2015, Pages 419-430

  Wu, Dingfeng ^a   Qiu, Tianyi ^a   Zhang, Qingchen ^a   Kang, Hong ^a   Yuan, Shaohua ^a   Zhu, Lixin ^b   Zhu, Ruixin ^a,c  

^a TONGJI UNIVERSITY   (China)

^b UNIVERSITY AT BUFFALO   (United States)

^c LIAONING UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACID HYDROLASE; ADENOSINE TRIPHOSPHATASE; COMPLEMENT; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOKINE; PROTON PUMP INHIBITOR; RETINOL;

ANTIGEN PRESENTATION; ARTICLE; CELL ORGANELLE; COMPUTER MODEL; DOWN REGULATION; DRUG SCREENING; GENE EXPRESSION; METABOLISM; UPREGULATION; ANIMAL; COMPUTER SIMULATION; DRUG EFFECTS; LIVER; MALE; SPRAGUE DAWLEY RAT;

ANIMALS; COMPUTER SIMULATION; GENE EXPRESSION; LIVER; MALE; PROTON PUMP INHIBITORS; RATS, SPRAGUE-DAWLEY;

EID: 84924858974     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx5003782     Document Type: Article

References (86)

1. Shi, S. and Klotz, U. (2008) Proton pump inhibitors: an update of their clinical use and pharmacokinetics Eur. J. Clin. Pharmacol. 64, 935-951
2. Besancon, M., Simon, A., Sachs, G., and Shin, J. M. (1997) Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents J. Biol. Chem. 272, 22438-22446
3. Hagiwara, T., Mukaisho, K., Nakayama, T., Sugihara, H., and Hattori, T. (2011) Long-term proton pump inhibitor administration worsens atrophic corpus gastritis and promotes adenocarcinoma development in Mongolian gerbils infected with Helicobacter pylori Gut 60, 624-630
4. Liu, W., Baker, S. S., Trinidad, J., Burlingame, A. L., Baker, R. D., Forte, J. G., Virtuoso, L. P., Egilmez, N. K., and Zhu, L. (2013) Inhibition of lysosomal enzyme activities by proton pump inhibitors J. Gastroenterol. 48, 1343-1352
5. Takashima, K., Mizukawa, Y., Morishita, K., Okuyama, M., Kasahara, T., Toritsuka, N., Miyagishima, T., Nagao, T., and Urushidani, T. (2006) Effect of the difference in vehicles on gene expression in the rat liver - analysis of the control data in the Toxicogenomics Project Database Life Sci. 78, 2787-2796
6. Tamura, K., Ono, A., Miyagishima, T., Nagao, T., and Urushidani, T. (2006) Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators J. Toxicol. Sci. 31, 471-490
7. Natsoulis, G., Pearson, C. I., Gollub, J., B, P. E., Ferng, J., Nair, R., Idury, R., Lee, M. D., Fielden, M. R., Brennan, R. J., Roter, A. H., and Jarnagin, K. (2008) The liver pharmacological and xenobiotic gene response repertoire Mol. Syst. Biol. 4, 175
8. Uehara, T., Ono, A., Maruyama, T., Kato, I., Yamada, H., Ohno, Y., and Urushidani, T. (2010) The Japanese toxicogenomics project: application of toxicogenomics Mol. Nutr. Food Res. 54, 218-227
9. Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D., and Lander, E. S. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring Science 286, 531-537
10. Pomeroy, S. L., Tamayo, P., Gaasenbeek, M., Sturla, L. M., Angelo, M., McLaughlin, M. E., Kim, J. Y., Goumnerova, L. C., Black, P. M., Lau, C., Allen, J. C., Zagzag, D., Olson, J. M., Curran, T., Wetmore, C., Biegel, J. A., Poggio, T., Mukherjee, S., Rifkin, R., Califano, A., Stolovitzky, G., Louis, D. N., Mesirov, J. P., Lander, E. S., and Golub, T. R. (2002) Prediction of central nervous system embryonal tumour outcome based on gene expression Nature 415, 436-442
11. Wedemeyer, R. S. and Blume, H. (2014) Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update Drug Saf. 37, 201-211
12. Curi-Pedrosa, R., Daujat, M., Pichard, L., Ourlin, J. C., Clair, P., Gervot, L., Lesca, P., Domergue, J., Joyeux, H., and Fourtanier, G. 1994, Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture J. Pharmacol. Exp. Ther. 269, 384-392
13. Masubuchi, N. and Okazaki, O. (1997) An evaluation of the CYP1A induction potential of pantoprazole in primary rat hepatocytes: a comparison with other proton pump inhibitors Chem.-Biol. Interact. 107, 63-74
14. Yoshinari, K., Ueda, R., Kusano, K., Yoshimura, T., Nagata, K., and Yamazoe, Y. (2008) Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements Biochem. Pharmacol. 76, 139-145
15. Ma, Q. and Lu, A. Y. (2007) CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies Drug Metab. Dispos. 35, 1009-1016
16. West, K. P., Jr. and Darnton-Hill, I. (2008) Vitamin A Deficiency, in Nutrition and Health in Developing Countries, pp 377-433, Springer, New York.
17. Moraitis, E., Eleftheriou, D., Cale, C., Pilkington, C., and Brogan, P. (2014) A51: c1q deficiency and autoimmunity-a single centre experience Arthritis Rheum. 66 (Suppl 11) S76
18. Lopez-Lera, A., J, M. T.-C., Garrido, S., Morales, A., and Lopez-Trascasa, M. (2014) Rothmund-Thomson syndrome and glomerulonephritis in a homozygous C1q-deficient patient due to a Gly164Ser C1qC mutation J. Invest. Dermatol. 134, 1152-1154
19. Mohlin, F. C. and Blom, A. M. (2014) Purification and functional characterization of C4b-binding protein (C4BP) Methods Mol. Biol. 1100, 169-176
20. Gigli, I., Fujita, T., and Nussenzweig, V. (1979) Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator Proc. Natl. Acad. Sci. U.S.A. 76, 6596-6600
21. Seya, T., Nakamura, K., Masaki, T., Ichihara-Itoh, C., Matsumoto, M., and Nagasawa, S. (1995) Human factor H and C4b-binding protein serve as factor I-cofactors both encompassing inactivation of C3b and C4b Mol. Immunol. 32, 355-360
22. Blom, A. M., Kask, L., and Dahlback, B. (2003) CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b Mol. Immunol. 39, 547-556
23. Degn, S. E., Jensenius, J. C., and Thiel, S. (2011) Disease-causing mutations in genes of the complement system Am. J. Hum. Genet. 88, 689-705
24. Alba-Dominguez, M., Lopez-Lera, A., Garrido, S., Nozal, P., Gonzalez-Granado, I., Melero, J., Soler-Palacin, P., Camara, C., and Lopez-Trascasa, M. (2012) Complement factor I deficiency: a not so rare immune defect: characterization of new mutations and the first large gene deletion Orphanet J. Rare Dis. 7, 42
25. Sadallah, S., Gudat, F., Laissue, J. A., Spath, P. J., and Schifferli, J. A. (1999) Glomerulonephritis in a patient with complement factor I deficiency Am. J. Kidney Dis. 33, 1153-1157
26. Markovic, S. N., Inwards, D. J., and Phyliky, R. P. (2000) Acquired C1 esterase inhibitor deficiency Ann. Int. Med. 133, 839
27. McLean-Tooke, A. (2014) Angioedema secondary to angiotensin converting enzyme inhibitors is not due to C1 esterase inhibitor deficiency Pediatr. Radiol. 44, 897-898
28. Smith, R. J., Harris, C. L., and Pickering, M. C. (2011) Dense deposit disease Mol. Immunol. 48, 1604-1610
29. Meyer, U. A. (1996) Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions Yale J. Biol. Med. 69, 203-209
30. Martin, R. M., Dunn, N. R., Freemantle, S., and Shakir, S. (2000) The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies Br. J. Clin. Pharmacol. 50, 366-372
31. Sarzynski, E., Puttarajappa, C., Xie, Y., Grover, M., and Laird-Fick, H. (2011) Association between proton pump inhibitor use and anemia: a retrospective cohort study Dig. Dis. Sci. 56, 2349-2353
32. Bowlby, H. A. and Dickens, G. R. (1994) Angioedema and urticaria associated with omeprazole confirmed by drug rechallenge Pharmacotherapy 14, 119-122
33. Haeney, M. R. (1992) Angio-edema and urticaria associated with omeprazole Br. Med. J. 305, 870
34. Polimeni, G., Cutroneo, P., Gallo, A., Gallo, S., Spina, E., and Caputi, A. P. (2007) Rabeprazole and psychiatric symptoms Ann. Pharmacother. 41, 1315-1317
35. Brewster, U. C. and Perazella, M. A. (2007) Proton pump inhibitors and the kidney: critical review Clin. Nephrol. 68, 65-72
36. Harmark, L., van der Wiel, H. E., de Groot, M. C., and van Grootheest, A. C. (2007) Proton pump inhibitor-induced acute interstitial nephritis Br. J. Clin. Pharmacol. 64, 819-823
37. Menges, M., Muller, M., and Zeitz, M. (2001) Increased acid and bile reflux in Barretts esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy Am. J. Gastroenterol. 96, 331-337
38. Arnold, R. (1994) Safety of proton pump inhibitors - an overview Aliment. Pharmacol. Ther. 8 (Suppl 1) 65-70
39. Dam, C. and Bygum, A. (2008) Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors Acta Derm.-Venereol. 88, 87-89
40. Bracke, A., Nijsten, T., Vandermaesen, J., Meuleman, L., and Lambert, J. (2005) Lansoprazole-induced subacute cutaneous lupus erythematosus: two cases Acta Derm.-Venereol. 85, 353-354
41. Sheen, E. and Triadafilopoulos, G. (2011) Adverse effects of long-term proton pump inhibitor therapy Dig. Dis. Sci. 56, 931-950
42. Nealis, T. B. and Howden, C. W. (2008) Is there a dark side to long-term proton pump inhibitor therapy? Am. J. Ther. 15, 536-542
43. Clark, D. W. and Strandell, J. (2006) Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur. J. Clin. Pharmacol. 62, 473-479
44. Sanchez Garrido, A. (2007) Omeprazole-induced acute cholestatic hepatitis Gastroenterol. Hepatol. 30, 54
45. Schonhofer, P. S., Werner, B., and Troger, U. (1997) Ocular damage associated with proton pump inhibitors Br. Med. J. 314, 1805
46. Aalkjaer, C. and Mulvany, M. J. (1988) Effect of changes in intracellular pH on the contractility of rat resistance vessels Prog. Biochem. Pharmacol. 23, 150-158
47. Laheij, R. J., Sturkenboom, M. C., Hassing, R.-J., Dieleman, J., Stricker, B. H., and Jansen, J. B. (2004) Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs J. Am. Med. Assoc. 292, 1955-1960
48. Canani, R. B., Cirillo, P., Roggero, P., Romano, C., Malamisura, B., Terrin, G., Passariello, A., Manguso, F., Morelli, L., and Guarino, A. (2006) Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children Pediatrics 117, e817-820
49. Zlabek, J. A. and Anderson, C. G. (2002) Lansoprazole-induced thrombocytopenia Ann. Pharmacother. 36, 809-811
50. Watson, T. D., Stark, J. E., and Vesta, K. S. (2006) Pantoprazole-induced thrombocytopenia Ann. Pharmacother. 40, 758-761
51. Cockayne, S. E., Glet, R. J., Gawkrodger, D. J., and McDonagh, A. J. (1999) Severe erythrodermic reactions to the proton pump inhibitors omeprazole and lansoprazole Br. J. Dermatol. 141, 173-175
52. Rebuck, J. A., Rybak, M. J., Ramos, D. P., and Weingarten, C. M. (1998) Omeprazole-induced exfoliative dermatitis Pharmacotherapy 18, 877-879
53. Epelde Gonzalo, F. D., Boada Montagut, L., and Tomas Vecina, S. (1995) Exfoliative dermatitis related to omeprazole Ann. Pharmacother. 29, 82-83
54. Moriyama, Y., Patel, V., Ueda, I., and Futai, M. (1993) Evidence for a common binding site for omeprazole and N-ethylmaleimide in subunit A of chromaffin granule vacuolar-type H(+)-ATPase Biochem. Biophys. Res. Commun. 196, 699-706
55. De Milito, A., Canese, R., Marino, M. L., Borghi, M., Iero, M., Villa, A., Venturi, G., Lozupone, F., Iessi, E., Logozzi, M., Della Mina, P., Santinami, M., Rodolfo, M., Podo, F., Rivoltini, L., and Fais, S. (2010) pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity Int. J. Cancer 127, 207-219
56. Spugnini, E. P., Citro, G., and Fais, S. (2010) Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy J. Exp. Clin. Cancer Res. 29, 44
57. Duffield, J. S. (2003) The inflammatory macrophage: a story of Jekyll and Hyde Clin. Sci. 104, 27-38
58. Gordon, S. (2003) Alternative activation of macrophages Nat. Rev. Immunol. 3, 23-35
59. Ma, J., Chen, T., Mandelin, J., Ceponis, A., Miller, N. E., Hukkanen, M., Ma, G. F., and Konttinen, Y. T. (2003) Regulation of macrophage activation Cell. Mol. Life Sci. 60, 2334-2346
60. Arango Duque, G. and Descoteaux, A. (2014) Macrophage cytokines: involvement in immunity and infectious diseases Front. Immunol. 5, 491
61. Carta, S., Lavieri, R., and Rubartelli, A. (2013) Different members of the IL-1 family come out in different ways: DAMPs vs. cytokines? Front. Immunol. 4, 123
62. Garg, S., Sharma, M., Ung, C., Tuli, A., Barral, D. C., Hava, D. L., Veerapen, N., Besra, G. S., Hacohen, N., and Brenner, M. B. (2011) Lysosomal trafficking, antigen presentation, and microbial killing are controlled by the Arf-like GTPase Arl8b Immunity 35, 182-193
63. Martin de Argila, C. (2005) Safety of potent gastric acid inhibition Drugs 65 (Suppl 1) 97-104
64. Stockbruegger, R. (1985) Bacterial overgrowth as a consequence of reduced gastric acidity Scand. J. Gastroenterol. 20, 7-15
65. Ruddell, W. S., Axon, A. T., Findlay, J. M., Bartholomew, B. A., and Hill, M. J. (1980) Effect of cimetidine on the gastric bacterial flora Lancet 1, 672-674
66. Bamberg, P., Caswell, C. M., Frame, M. H., Lam, S. K., and Wong, E. C. (1992) A meta-analysis comparing the efficacy of omeprazole with H2-receptor antagonists for acute treatment of duodenal ulcer in Asian patients J. Gastroenterol. Hepatol. 7, 577-585
67. Eriksson, S., Langstrom, G., Rikner, L., Carlsson, R., and Naesdal, J. (1995) Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis Eur. J. Gastroenterol. Hepatol. 7, 467-475
68. Gisbert, J. P., Gonzalez, L., Calvet, X., Roque, M., Gabriel, R., and Pajares, J. M. (2001) Proton pump inhibitors versus H2-antagonists: a meta-analysis of their efficacy in treating bleeding peptic ulcer Aliment. Pharmacol. Ther. 15, 917-926
69. el-Zimaity, H. M., Jackson, F. W., and Graham, D. Y. (1997) Fundic gland polyps developing during omeprazole therapy Am. J. Gastroenterol. 92, 1858-1860
70. Choudhry, U., Boyce, H. W., Jr, and Coppola, D. (1998) Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics Am. J. Clin. Pathol. 110, 615-621
71. Graham, J. R. (1992) Gastric polyposis: onset during long-term therapy with omeprazole Med. J. Aust. 157, 287-288
72. Jalving, M., Koornstra, J. J., Wesseling, J., Boezen, H. M., S, D. E. J., and Kleibeuker, J. H. (2006) Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy Aliment. Pharmacol. Ther. 24, 1341-1348
73. Campbell, M. S., Obstein, K., Reddy, K. R., and Yang, Y.-X. (2008) Association between proton pump inhibitor use and spontaneous bacterial peritonitis Dig. Dis. Sci. 53, 394-398
74. Fardet, L., Izzedine, H., Ciroldi, M., Tiev, K. P., and Cabane, J. (2002) Pantoprazole-induced recurrent anaphylactic shock Am. J. Gastroenterol. 97, 2933
75. Natsch, S., Vinks, M. H., Voogt, A. K., Mees, E. B., and Meyboom, R. H. (2000) Anaphylactic reactions to proton-pump inhibitors Ann. Pharmacother. 34, 474-476
76. Burlinson, B., Morriss, S. H., Gatehouse, D. G., and Tweats, D. J. (1990) Genotoxicity studies of gastric acid inhibiting drugs Lancet 335, 419-420
77. Termanini, B., Gibril, F., Sutliff, V. E., Yu, F., Venzon, D. J., and Jensen, R. T. (1998) Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome Am. J. Med. 104, 422-430
78. Dharmarajan, T. S., Kanagala, M. R., Murakonda, P., Lebelt, A. S., and Norkus, E. P. (2008) Do acid-lowering agents affect vitamin B12 status in older adults? J. Am. Med. Dir. Assoc. 9, 162-167
79. Koop, H. (1992) Review article: metabolic consequences of long-term inhibition of acid secretion by omeprazole Aliment. Pharmacol. Ther. 6, 399-406
80. Hoorn, E. J., van der Hoek, J., de Man, R. A., Kuipers, E. J., Bolwerk, C., and Zietse, R. (2010) A case series of proton pump inhibitor-induced hypomagnesemia Am. J. Kidney Dis. 56, 112-116
81. Cundy, T. and Dissanayake, A. (2008) Severe hypomagnesaemia in long-term users of proton-pump inhibitors Clin. Endocrinol. 69, 338-341
82. Mizunashi, K., Furukawa, Y., Katano, K., and Abe, K. (1993) Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans Calcif. Tissue Int. 53, 21-25
83. Tuukkanen, J. and Vaananen, H. K. (1986) Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro Calcif. Tissue Int. 38, 123-125
84. Borum, M. L. and Cannava, M. (1997) Diffuse alopecia associated with omeprazole Am. J. Gastroenterol. 92, 1576
85. McCarthy, D. M., McLaughlin, T., Yazdani, C., El Serag, H. B., and Griffis, D. L. (2002) Effects of co-therapy with early proton pump inhibitors (PPIs) on the occurrence of side effects of other drugs with potential for interaction with PPIs: A cohort study Gastroenterology 122, A210-A210
86. Labenz, J., Petersen, K. U., Rosch, W., and Koelz, H. R. (2003) A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole Aliment. Pharmacol. Ther. 17, 1015-1019